VBI Vaccines Inc.
Edit

VBI Vaccines Inc.

https://www.vbivaccines.com/
Last activity: 22.03.2024
Categories: BioTechDesignDevelopmentHumanLearnManufacturingNewsPlatformResearchTechnology
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac®, which is approved for use in Israel and 10 other countries and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus (CMV) expertise with the eVLP platform technology, VBI’s lead eVLP program candidates include a prophylactic CMV vaccine candidate and a glioblastoma (GBM) vaccine immunotherapeutic candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Likes
537
Followers
2.31K
Website visits
7.6K /mo.
Mentions
24
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Phone: +1 617-830-3031
Total raised: $50M
Founded date: 2001

Investors 4

Funding Rounds 1

DateSeriesAmountInvestors
27.05.2020-$50M-

Mentions in press and media 24

DateTitleDescriptionSource
22.03.2024Brii Biosciences Provides Corporate Update and Reports Full-...Transitioning HBV cure programs into multiple late-stage combination studies with interim results th...en.prnasia...
27.12.2021Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial o...DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo...en.prnasia...
09.12.2021VBI Vaccines : Announces Filing of New Drug Submission for 3...VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Can...marketscre...
02.12.2021VBI Vaccines : to Present New Overall Survival Data from Pha...VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World ...marketscre...
01.12.2021VBI Vaccines : Announces FDA Approval of PreHevbrio™ for the...VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults - Pre...marketscre...
08.11.2021VBI Vaccines Announces Third Quarter 2021 Financial Results ...VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Hepatiti...marketscre...
01.11.2021VBI Vaccines Announces e-Poster Presentation of 3-Antigen Pr...VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at T...marketscre...
14.10.2021VBI Vaccines : Announces Publication of Results from Pivotal...VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the purs...marketscre...
13.10.2021VBI Vaccines : Press Release dated October 13, 2021 (furnish...Exhibit 99.1 VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of ...marketscre...
29.09.2021VBI Vaccines : Announces New Preclinical Data and Initiation...VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broa...marketscre...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In